Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

Regulatory

January 29, 2026

Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

Read more

January 16, 2026

Chairman of the Board of Egetis Therapeutics acquires shares

Read more

January 8, 2026

Egetis Therapeutics to Host Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Read more

Upcoming event

February 26, 2026

Year-end Report Q4 2025 webcast

Latest presentation

November 25, 2025

Q3 2025 report webcast (replay)

Latest Report

November 25, 2025

Interim report Q3 2025

Calendar and upcoming reports

February 26, 2026 (7:00am CET)

Year-end Report Q4 2025

March 10-11, 2026

Leerink Global Healthcare Conference (Miami, FL)

March 12, 2026

DNB Carnegie Healthcare Conference (Stockholm)

April 14, 2026

Annual General Meeting

April 16, 2026

van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 29, 2026 (7:00am CEST)

Interim Report Q1 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]